Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
Financials (USD)
Sales 2021 | 28.9M | Sales 2022 | 36.94M | Capitalization | 5.79M |
---|---|---|---|---|---|
Net income 2021 | -49M | Net income 2022 | -57M | EV / Sales 2021 | -0.2 x |
Net cash position 2021 | 39.64M | Net cash position 2022 | 7.19M | EV / Sales 2022 | -0.04 x |
P/E ratio 2021 |
-0.53
x | P/E ratio 2022 |
-0.09
x | Employees | 39 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.05% |
1 day | -99.00% |
Managers | Title | Age | Since |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 23-07-06 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 23-06-29 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Stephen Webster
BRD | Director/Board Member | 63 | 16-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.000001 | -99.00% | 280 |
Delayed Quote OTC Markets, May 08, 2024 at 11:44 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
0.00% | 3 | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- NBRVF Stock